Preferred Label : Monomethyl Auristatin E;
NCIt synonyms : (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide; L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-
methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-; N(sup 2)-(N-methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2-
phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N(sup
1)-methyl-L-valinamide; MMAE; Monomethylauristatin E;
NCIt definition : A dolastatin-10 peptide derivative with potent antimitotic activity and potential
antineoplastic activity as part of an antibody-drug conjugate (ADC). Monomethyl auristatin
E (MMAE) binds to tubulin, blocks tubulin polymerization, and inhibits microtubule
formation, which results in both disruption of mitotic spindle assembly and arrest
of tumor cells in the M phase of the cell cycle. To minimize toxicity and maximize
efficacy, MMAE is conjugated, via a cleavable peptide linker, to a monoclonal antibody
that specifically targets a patient's tumor. The linker is stable in the extracellular
milieu but is readily cleaved to release MMAE following binding and internalization
of the ADC by the target cells.;
UNII : V7I58RC5EJ;
CAS number : 474645-27-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 474645-27-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Origin ID : C122637;
UMLS CUI : C1565020;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
